SCHEMBL2096586

SCHEMBL2096586

OCCCc1ccc2occcc1-2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.34
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 4/20 0.34
CASP6 P55212 2/20 0.34
NPC1 O15118 2/20 0.34
POLB P06746 5/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 1/20 0.33
PTPN1 P18031 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
THRB P10828 4/20 0.32
MEN1 O00255 3/20 0.32
RECQL P46063 3/20 0.32
KMT2A Q03164 3/20 0.32
TDP1 Q9NUW8 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MCL1 Q07820 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096513 0.81 ALDH1A1 (0.37) MAPTALDH1A1KDM4ECASP6NPC1
SCHEMBL2094790 0.79 ALDH1A1 (0.34) MAPTALDH1A1KDM4ECASP6NPC1
SCHEMBL452969 0.78 USP2 (0.32) ALDH1A1TDP1HPGDUSP2
SCHEMBL2095889 0.78 OPRM1 (0.38) MAPTALDH1A1KDM4ENPC1POLB
SCHEMBL27645167 0.77 USP2 (0.31) ALDH1A1TDP1HPGDUSP2
SCHEMBL448512 0.77 ALDH1A1 (0.37) ALDH1A1TDP1HPGDUSP2ALOX15
SCHEMBL27666122 0.76 ALDH1A1 (0.33) ALDH1A1TDP1HPGDUSP2ALOX15
SCHEMBL2091925 0.76
SCHEMBL2095737 0.75 KDM4E (0.37) MAPTALDH1A1KDM4ECASP6NPC1
SCHEMBL27645170 0.74 OPRM1 (0.32) OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MAPT 4299/4885ALDH1A1 412/4885KDM4E 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.